Compare Revvity Inc (RVTY) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Shell PLC — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Shell PLC trades at $95.6 (market cap $271.34B). The key difference: Shell PLC is far larger — about 19.1× Revvity Inc's market cap, and Shell PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals.
| RVTY | SHEL | |
|---|---|---|
Market Cap | $14.18B | $271.34B |
Sector | Technology | Energy |
52-Week High | $130.94 | $95.60 |
52-Week Low | $82.26 | $70.31 |
Enterprise Value | $16.50B | $313.04B |
Dividend Yield | 0.22% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Shell (SHEL) trades at $95.32, up 2.55% with strong bullish momentum as crude oil prices rally. The stock shows robust fundamentals with a P/E of 10.54 and net income margin of 8.76%, while recent Q2 2026 earnings beat expectations. Technical indicators signal bullish sentiment with the price near resistance at $96. Recent acquisitions including ARC Resources and strategic partnerships with BP expand Shell's deepwater footprint, driving growth prospects.
Outlook remains positive with analyst consensus price target of $101 (6% upside), supported by 61.5% buy ratings. Key risks include oil price volatility and geopolitical tensions, but strong cash flow generation and strategic expansions position SHEL for sustained growth. The current valuation appears attractive relative to earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
